How useful are serum IGF-I measurements for managing GH replacement therapy in adults and children?

Pituitary

Volumn 15, Issue 2, 2012, Pages 126-134

  Pawlikowska Haddal, Anna ^a,b   Cohen, Pinchas ^a,b   Cook, David M ^c  

^a MATTEL CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Growth hormone treatment; IGF I; IGF I based dosing; Individualized dosing

Indexed keywords

GROWTH HORMONE; HUMAN GROWTH HORMONE; INSULIN; RECOMBINANT GROWTH HORMONE; SOMATOMEDIN C;

ADULT; CANCER RISK; CHILD; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG FORMULATION; DRUG MECHANISM; DRUG MEGADOSE; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE RELEASE; HORMONE SUBSTITUTION; HUMAN; IMMUNORADIOMETRIC ASSAY; LEUKEMIA; LOW DRUG DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RADIOIMMUNOASSAY; RECOMMENDED DRUG DOSE; REVIEW;

ADOLESCENT; ADULT; AGED; CHILD; FEMALE; HORMONE REPLACEMENT THERAPY; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84861455859     PISSN: 1386341X     EISSN: 15737403     Source Type: Journal    
DOI: 10.1007/s11102-011-0343-y     Document Type: Review

References (62)

1. American Association of Clinical Endocrinologists (2003) American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in adults and children-2003 update. Endocr Pract 9:64-76
2. Wilson TA, Rose SR, Cohen P, Rogol AD, Backeljauw P, Brown R, Hardin DS, Kemp SF, Lawson M, Radovick S, Rosenthal SM, Silverman L, Speiser P (2003) Update of guidelines for the use of growth hormone in children: the Lawson Wilkins pediatric endocrinology society drug and therapeutics committee. J Pediatr 143:415-421 (Pubitemid 37355966)
3. Cook DM, Yuen KC, Biller BM, Kemp SF, Vance ML (2009) American Association of clinical endocrinologists medical guidelines for clinical practice for growth hormone use in growth hormone-deficient adults and transition patients-2009 update. Endocr Pract 15(Suppl 2):1-29
4. Gibney J, Johannsson G (2004) Long-Term monitoring of insulinlike growth factor I in adult growth hormone deficiency: A critical appraisal. Horm Res 62(Suppl 1):66-72 (Pubitemid 40532960)
5. Hoffman AR, Kuntze JE, Baptista J, Baum HB, Baumann GP, Biller BM, Clark RV, Cook D, Inzucchi SE, Kleinberg D, Klibanski A, Phillips LS, Ridgway EC, Robbins RJ, Schlechte J, Sharma M, Thorner MO, Vance ML (2004) Growth hormone (GH) replacement therapy in adult-onset GH deficiency: effects on body composition in men and women in a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab 89:2048-2056 (Pubitemid 38619832)
6. Cohen P, Germak J, Rogol AD, Weng W, Kappelgaard AM, Rosenfeld RG (2010) Variable degree of growth hormone (GH) and insulin-like growth factor (IGF) sensitivity in children with idiopathic short stature compared with GH-deficient patients: evidence from an IGF-based dosing study of short children. J Clin Endocrinol Metab 95:2089-2098
7. Brabant G, Wallaschofski H (2007) Normal levels of serum IGFI: determinants and validity of current reference ranges. Pituitary 10:129-133 (Pubitemid 46863727)
8. Growth Hormone Research Society (2000) Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH research society. GH research society. J Clin Endocrinol Metab 85:3990-3993
9. Johannsson G, Rosen T, Bengtsson BA (1997) Individualized dose titration of growth hormone (GH) during GH replacement in hypopituitary adults. Clin Endocrinol (Oxf) 47:571-581 (Pubitemid 27496332)
10. Chihara K, Kato Y, Shimatsu A, Tanaka T, Kohno H (2008) Efficacy and safety of individualized growth hormone treatment in adult Japanese patients with growth hormone deficiency. Growth Horm IGF Res 18:394-403 (Pubitemid 351944034)
11. Hoffman AR, Strasburger CJ, Zagar A, Blum WF, Kehely A, Hartman ML (2004) Efficacy and tolerability of an individualized dosing regimen for adult growth hormone replacement therapy in comparison with fixed body weight-based dosing. J Clin Endocrinol Metab 89:3224-3233 (Pubitemid 38960691)
12. Park P, Cohen P (2004) The role of insulin-like growth factor I monitoring in growth hormone-Treated children. Horm Res 62(Suppl 1):59-65 (Pubitemid 40529152)
13. Ranke MB, Schweizer R, Wollmann HA, Schwarze P (1999) Dosing of growth hormone in growth hormone deficiency. Horm Res 51(Suppl 3):70-74
14. Rosenfeld RG, Cohen P (2008) Disorders of growth hormone/insulin-like growth factor secretion and action. In: Sperling MA (ed) Pediatric endocrinology, 3rd edn. Saunders, Philadelphia, pp 254-334
15. Denson LA (2008) Growth hormone therapy in children and adolescents: pharmacokinetic/pharmacodynamic considerations and emerging indications. Expert Opin Drug Metab Toxicol 4:1569-1580
16. Faje AT, Barkan AL (2010) Basal, but not pulsatile, growth hormone secretion determines the ambient circulating levels of insulin-like growth factor-I. J Clin Endocrinol Metab 95: 2486-2491
17. Frystyk J, Freda P, Clemmons DR (2010) The current status of IGF-I assays-A 2009 update. Growth Horm IGF Res 20:8-18
18. Hoffman DM, O'Sullivan AJ, Baxter RC, Ho KK (1994) Diagnosis of growth-hormone deficiency in adults. Lancet 343: 1064-1068 (Pubitemid 24128205)
19. O'Connor KG, Tobin JD, Harman SM, Plato CC, Roy TA, Sherman SS, Blackman MR (1998) Serum levels of insulin-like growth factor-I are related to age and not to body composition in healthy women and men. J Gerontol Biol Sci Med Sci 53:M176-M182 (Pubitemid 28232598)
20. Schneider HJ, Saller B, Klotsche J, Marz W, Erwa W, Wittchen HU, Stalla GK (2006) Opposite associations of age-dependent insulin-like growth factor-I standard deviation scores with nutritional state in normal weight and obese subjects. Eur J Endocrinol 154:699-706 (Pubitemid 43810856)
21. Franco C, Veldhuis JD, Iranmanesh A, Brandberg J, Lonn L, Andersson B, Bengtsson BA, Svensson J, Johannsson G (2006) Thigh intermuscular fat is inversely associated with spontaneous GH release in post-menopausal women with abdominal obesity. Eur J Endocrinol 155:261-268 (Pubitemid 44269442)
22. Casanueva FF, Villanueva L, Dieguez C, Diaz Y, Cabranes JA, Szoke B, Scanlon MF, Schally AV, Fernandez-Cruz A (1987) Free fatty acids block growth hormone (GH) releasing hormonestimulated GH secretion in man directly at the pituitary. J Clin Endocrinol Metab 65:634-642 (Pubitemid 17160242)
23. Van Dam PS, Smid HE, de Vries WR, Niesink M, Bolscher E, Waasdorp EJ, Dieguez C, Casanueva FF, Koppeschaar HP (2000) Reduction of free fatty acids by acipimox enhances the growth hormone (GH) responses to GH-releasing peptide 2 in elderly men. J Clin Endocrinol Metab 85:4706-4711 (Pubitemid 32157656)
24. Chen JW, Nielsen MF, Caumo A, Vilstrup H, Christiansen JS, Frystyk J (2006) Changes in bioactive IGF-I and IGF-binding protein-1 during an oral glucose tolerance test in patients with liver cirrhosis. Eur J Endocrinol 155:285-292 (Pubitemid 44269445)
25. Kwan AY, Hartman ML (2007) IGF-I measurements in the diagnosis of adult growth hormone deficiency. Pituitary 10:151-157 (Pubitemid 46876190)
26. Iglesias P, Diez JJ, Fernandez-Reyes MJ, Mendez J, Bajo MA, Aguilera A, Selgas R (2004) Growth hormone, IGF-I and its binding proteins (IGFBP-1 and -3) in adult uraemic patients undergoing peritoneal dialysis and haemodialysis. Clin Endocrinol (Oxf) 60:741-749 (Pubitemid 38788083)
27. Juul A (2003) Serum levels of insulin-like growth factor I and its binding proteins in health and disease. Growth Horm IGF Res 13:113-170 (Pubitemid 36986557)
28. Clauson PG, Brismar K, Hall K, Linnarsson R, Grill V (1998) Insulin-like growth factor-I and insulin-like growth factor binding protein-1 in a representative population of type 2 diabetic patients in Sweden. Scand J Clin Lab Invest 58:353-360 (Pubitemid 28396224)
29. Higham CE, Jostel A, Trainer PJ (2007) IGF-I measurements in the monitoring of GH therapy. Pituitary 10:159-163 (Pubitemid 46863730)
30. Bidlingmaier M, Kim J, Savoy C, Kim MJ, Ebrecht N, de la Motte S, Strasburger CJ (2006) Comparative pharmacokinetics and pharmacodynamics of a new sustained-release growth hormone (GH), LB03002, versus daily GH in adults with GH deficiency. J Clin Endocrinol Metab 91:2926-2930 (Pubitemid 44271737)
31. Peter F, Savoy C, Ji HJ, Juhasz M, Bidlingmaier M, Saenger P (2009) Pharmacokinetic and pharmacodynamic profile of a new sustained-release GH formulation, LB03002, in children with GH deficiency. Eur J Endocrinol 160:349-355
32. Milani D, Carmichael JD, Welkowitz J, Ferris S, Reitz RE, Danoff A, Kleinberg DL (2004) Variability and reliability of single serum IGF-I measurements: impact on determining predictability of risk ratios in disease development. J Clin Endocrinol Metab 89:2271-2274 (Pubitemid 38619863)
33. Growth Hormone Research Society, Pituitary Society (2004) Biochemical assessment and long-Term monitoring in patients with acromegaly: statement from a joint consensus conference of the Growth Hormone Research Society and the Pituitary Society. J Clin Endocrinol Metab 89:3099-3102
34. Burns C, Rigsby P, Moore M, Rafferty B (2009) The first international standard for Insulin-like Growth Factor-1 (IGF-1) for immunoassay: preparation and calibration in an international collaborative study. Growth Horm IGF Res 19:457-462
35. Park P, Cohen P (2005) Insulin-like growth factor I (IGF-I) measurements in growth hormone (GH) therapy of idiopathic short stature (ISS). Growth Horm IGF Res 15(Suppl A):S13-S20 (Pubitemid 41030766)
36. Johannsson G (2007) Management of adult growth hormone deficiency. Endocrinol Metab Clin North Am 36:203-220
37. Yuen K, Frystyk J, Umpleby M, Fryklund L, Dunger D (2004) Changes in free rather than total insulin-like growth factor-I enhance insulin sensitivity and suppress endogenous peak growth hormone (GH) release following short-Term low-dose GH administration in young healthy adults. J Clin Endocrinol Metab 89:3956-3964 (Pubitemid 39071499)
38. Cohen P, Rogol AD, Howard CP, Bright GM, Kappelgaard AM, Rosenfeld RG (2007) Insulin growth factor-based dosing of growth hormone therapy in children: A randomized, controlled study. J Clin Endocrinol Metab 92:2480-2486 (Pubitemid 47037346)
39. Labarta JI, Ruiz JA, Molina I, De AA, Mayayo E, Longas AF (2009) Growth and growth hormone treatment in short stature children born small for gestational age. Pediatr Endocrinol Rev 6(Suppl 3):350-357
40. de Zegher F, Maes M, Gargosky SE, Heinrichs C, Du Caju MV, Thiry G, De Schepper J, Craen M, Breysem L, Lofstrom A, Jonsson P, Bourguignon JP, Malvaux P, Rosenfeld RG (1996) High-dose growth hormone treatment of short children born small for gestational age. J Clin Endocrinol Metab 81:1887-1892 (Pubitemid 26152481)
41. Sas TC, Gerver WJ, De Bruin R, Mulder PG, Cole TJ, de Wouter W, Hokken-Koelega AC (2000) Body proportions during 6 years of GH treatment in children with short stature born small for gestational age participating in a randomised, double-blind, doseresponse trial. Clin Endocrinol (Oxf) 53:675-681 (Pubitemid 32096678)
42. Underwood LE, Attie KM, Baptista J (2003) Growth hormone (GH) dose-response in young adults with childhood-onset GH deficiency: A two-year, multicenter, multiple-dose, placebo-controlled study. J Clin Endocrinol Metab 88:5273-5280 (Pubitemid 37452727)
43. Cohen P, Bright GM, Rogol AD, Kappelgaard AM, Rosenfeld RG (2002) Effects of dose and gender on the growth and growth factor response to GH in GH-deficient children: implications for efficacy and safety. J Clin Endocrinol Metab 87:90-98 (Pubitemid 34084676)
44. van Teunenbroek A, de Muinck Keizer-Schrama S, Stijnen T, Jansen M, Otten BJ, Delemarre-van de Waal H, Vulsma T, Wit JM, Rouwe CW, Reeser HM, Gosen JJ, Rongen-Westerlaken C, Drop SL (1996) Yearly stepwise increments of the growth hormone dose results in a better growth response after four years in girls with Turner syndrome. Dutch working group on growth hormone. J Clin Endocrinol Metab 81:4013-4021 (Pubitemid 26383294)
45. Kamp GA, Zwinderman AH, van Doorn J, Hackeng W, Frolich M, Schonau E, Wit JM (2002) Biochemical markers of growth hormone (GH) sensitivity in children with idiopathic short stature: individual capacity of IGF-I generation after high-dose GH treatment determines the growth response to GH. Clin Endocrinol 57:315-325 (Pubitemid 35013810)
46. Cohen P, Rogol AD, Deal CL, Saenger P, Reiter EO, Ross JL, Chernausek SD, Savage MO, Wit JM (2008) Consensus statement on the diagnosis and treatment of children with idiopathic short stature: A summary of the growth hormone research society, the Lawson Wilkins pediatric endocrine society, and the European society for paediatric endocrinology workshop. J Clin Endocrinol Metab 93:4210-4217 (Pubitemid 352806728)
47. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M (2004) Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363:1346-1353 (Pubitemid 38529873)
48. Shaneyfelt T, Husein R, Bubley G, Mantzoros CS (2000) Hormonal predictors of prostate cancer: A meta-Analysis. J Clin Oncol 18:847-853 (Pubitemid 30106616)
49. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M (1998) Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351:1393-1396 (Pubitemid 28209997)
50. Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, Stampfer MJ (1999) Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 91:620-625 (Pubitemid 29194048)
51. Juul A, Scheike T, Davidsen M, Gyllenborg J, Jorgensen T (2002) Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: A population-based casecontrol study. Circulation 106:939-944 (Pubitemid 34925327)
52. Sklar CA, Mertens AC, Mitby P, Occhiogrosso G, Qin J, Heller G, Yasui Y, Robison LL (2002) Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: A report from the childhood cancer survivor study. J Clin Endocrinol Metab 87:3136-3141 (Pubitemid 34816355)
53. Monson JP (2003) Long-Term experience with GH replacement therapy: efficacy and safety. Eur J Endocrinol 148(Suppl 2):S9-S14 (Pubitemid 36531482)
54. Swerdlow AJ, Reddingius RE, Higgins CD, Spoudeas HA, Phipps K, Qiao Z, Ryder WD, Brada M, Hayward RD, Brook CG, Hindmarsh PC, Shalet SM (2000) Growth hormone treatment of children with brain tumors and risk of tumor recurrence. J Clin Endocrinol Metab 85:4444-4449 (Pubitemid 32157616)
55. Arnold JR, Arnold DF, Marland A, Karavitaki N, Wass JA (2009) GH replacement in patients with non-functioning pituitary adenoma (NFA) treated solely by surgery is not associated with increased risk of tumour recurrence. Clin Endocrinol (Oxf) 70:435-438
56. Karavitaki N, Warner JT, Marland A, Shine B, Ryan F, Arnold J, Turner HE, Wass JA (2006) GH replacement does not increase the risk of recurrence in patients with craniopharyngioma. Clin Endocrinol (Oxf) 64:556-560
57. Hatrick AG, Boghalo P, Bingham JB, Ayres AB, Sonksen PH, Russell-Jones DL (2002) GH replacement therapy in adult GHdeficient patients result in recurrence or increase in size of pituitary tumours. Eur J Endocrinol 146:807-811 (Pubitemid 34705073)
58. Bell J, Parker KL, Swinford RD, Hoffman AR, Maneatis T, Lippe B (2010) Long-Term safety of recombinant human growth hormone in children. J Clin Endocrinol Metab 95:167-177
59. Mauras N, Attie KM, Reiter EO, Saenger P, Baptista J (2000) High dose recombinant human growth hormone (GH) treatment of GH-deficient patients in puberty increases near-final height: A randomized, multicenter trial. J Clin Endocrinol Metab 85:3653-3660
60. US Food and Drug Administration (2011) Somatropin information. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafe tyInformationforPatientsandProviders/ucm237839.htm. Accessed 28 Mar 2011
61. Novo Nordisk (2010) Norditropin (somatropin [rDNA origin] injection) for subcutaneous use [prescribing information]. Novo Nordisk, Princeton
62. Eli Lilly and Company (2005) Humatrope Somatropin (rDNA Origin) for injection vials and cartridges [prescribing information]. Eli Lilly and Company, Indianapolis